

**QuidelOrtho
Transparency in Supply Chain
and
Modern Slavery Report**

For the Financial Year Ended December 28, 2025

1. Introduction

- 1.1 QuidelOrtho Corporation, a Delaware corporation (“**QuidelOrtho Corp.**”), and its subsidiaries (together, “**QuidelOrtho**”) are committed to preventing modern slavery in their business and supply chains.
- 1.2 This Transparency in Supply Chain and Modern Slavery Report (this “**Report**”) sets forth the steps taken by QuidelOrtho in the financial year ended December 28, 2025 (the “**Financial Year**”) to mitigate the risk of forced labor, child labor and human trafficking (collectively, “**modern slavery**”) from occurring in any part of its business or supply chains. This Report is made pursuant to California’s Transparency in Supply Chains Act on behalf of QuidelOrtho Corp., and the U.K.’s Modern Slavery Act 2015 (the “**UK Act**”) on behalf of Ortho-Clinical Diagnostics, a company incorporated under the laws of England and Wales (“**Ortho UK**”). For the avoidance of doubt, only the entities specified in the preceding sentence are subject to the Acts referred to above. Each of these entities comes within QuidelOrtho’s global compliance program, which is discussed throughout this Report.

2. Our Organizational Structure and Business

- 2.1 As of December 28, 2025, QuidelOrtho was comprised of 77 entities, including Ortho UK, which is a wholly owned subsidiary of QuidelOrtho Corp.
- 2.2 QuidelOrtho’s vision is to advance diagnostics to power a healthier future. With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity to clinicians and patients to help create better health outcomes. Our global infrastructure and commercial reach support our customers across more than 140 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S., U.K. and China and with sales centers, administrative offices and warehouses located across the world. Ortho UK manufactures certain of our immunoassay and immunohematology products that are distributed globally and also sells and distributes QuidelOrtho products.
- 2.3 QuidelOrtho’s corporate headquarters is located in San Diego, California, U.S. Our primary manufacturing facilities are located in the U.S. in Carlsbad, California, San Diego, California, Athens, Ohio, Raritan, New Jersey, Rochester, New York and Pompano Beach, Florida and Pencoed, Wales in the U.K. We also have a manufacturing facility in Changsha, China.
- 2.4 As of December 28, 2025, we had approximately 6,500 employees worldwide, with approximately 3,600 employees in the U.S. and approximately 2,900 employees outside of the U.S. We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care settings, blood banks and donor centers, as well as for individual, non-professional, over-the-counter use.

3. Our Supply Chains

- 3.1 Due to the diverse nature of our manufactured products and markets, we have a complex and geographically broad range of suppliers of raw material, goods and ancillary services that

contribute to our main production operations, such as transporters and carriers. QuidelOrtho, including Ortho UK, utilize the same global supply chains.

4. Our Policies on Modern Slavery and Contractual Controls

- 4.1 QuidelOrtho promotes honest, ethical and lawful conduct throughout our business. Our Code of Business Conduct and Ethics (the “**Code**”), which applies to all subsidiaries, is central to achieving these goals. Ethical behavior is the foundation to our success in achieving our business objectives and we recognize it is in our best interest to set standards for ourselves at all times in compliance with applicable laws, including not engaging in modern slavery, and to align ourselves with agents, representatives, suppliers and partners who have similar high standards of business conduct.
- 4.2 The Code applies to all directors, officers, employees, and temporary workers of QuidelOrtho (“**Company Employees**”). The Code contains general guidelines for conducting the business of QuidelOrtho with integrity, honesty and business ethics in compliance with applicable laws and specifically prohibits modern slavery abuses in our supply chain, facilities, or in carrying out our business.
- 4.3 Ethical and lawful behaviour is also a keystone of our dealings with service providers and suppliers. QuidelOrtho has adopted a Supplier and Distributor Code of Business Conduct and Ethics (the “**Supplier and Distributor Code**”), which sets forth the requirements and expectations that QuidelOrtho has for its vendors, service providers, contactors, consultants, representatives, and any of their respective employees or subcontractors (“**Suppliers and Distributors**”). The Supplier and Distributor Code expressly prohibits Suppliers and Distributors from using forced or involuntary labor whether in the form of prison labor, indentured labor, bonded labor, or any other form of modern slavery.
- 4.4 QuidelOrtho seeks to do business with suppliers that have similar values, ethics and moral business practices, including those related to modern slavery. Our vendor and supplier contract forms require our suppliers to comply with applicable laws and our Supplier and Distributor Code.
- 4.5 Under the Code, all Company Employees have a duty to report any known or suspected violation of the Code, including violations of the laws, rules, regulations or policies that apply to QuidelOrtho. Under our Supplier and Distributor Code, Suppliers and Distributors are also encouraged to report known or suspected unethical behavior or violations of applicable laws through the course of business with QuidelOrtho. QuidelOrtho maintains an Ethics Hotline, which is available 24 hours a day, 7 days a week and is one method in which our Company Employees, Suppliers and Distributors and other third parties can raise concerns regarding potential modern slavery in our business or supply chains. Individuals may remain anonymous and will not be required to reveal their identities in the calls to the QuidelOrtho Ethics Hotline.
- 4.6 We believe that adherence to and compliance with our policies and procedures, including the Code and our Supplier and Distributor Code, mitigates the risks of modern slavery occurring in our business or supply chains. A copy of our Code can be found on our website [here](#). A copy of our Supplier and Distributor Code can be found on our website [here](#).

5. Risk Assessment and Due Diligence Processes

- 5.1 During the Financial Year, QuidelOrtho conducted third party due diligence, where appropriate, before contracting with potential suppliers, service providers, distributors and similar intermediaries. Preliminary risk assessments were performed by QuidelOrtho on potential suppliers with assessment questionnaires. Upon review of the questionnaires, if necessary, QuidelOrtho may follow-up with an in-depth assessment conducted by either an internal supplier assessment team, or a third-party auditing firm.

- 5.2 QuidelOrtho has adopted a [Conflict Minerals Policy Statement](#), which establishes QuidelOrtho's commitment to complying with the Organisation for Economic Co-operation and Development Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas, as well as the applicable requirements of Section 1502 of the Dodd-Frank Act.
- 5.3 From time to time, QuidelOrtho entities may conduct audits of direct material suppliers to evaluate supplier compliance with our standards, which includes compliance with applicable laws. Direct material suppliers may also be evaluated through audits on their compliance with the terms of our supply agreements. The audits may be conducted by either a QuidelOrtho supplier assessment team, or a third-party auditing firm. Following audits, suppliers may be required to produce a corrective action plan to outline how the supplier will resolve any issues uncovered in the audits.
- 5.4 During the Financial Year, we also conducted due diligence and right to work checks on our employees as appropriate to safeguard against human trafficking and forced labor.

6. Our Modern Slavery Risk Profile

- 6.1 Within our business operations, we believe we have implemented fair and responsible employment practices to protect and promote Company Employees' rights. We therefore believe that the risk of modern slavery in our business is low.
- 6.2 However, we recognize that the risks of modern slavery may be present in our supply chain due to our business relationships. The workers of our Suppliers and Distributors are not employed directly by QuidelOrtho, so we have less visibility over their working conditions and employment terms. Nonetheless, as described above, we have processes in place designed to address such risks.

7. Training

- 7.1 QuidelOrtho requires all Company Employees to undergo annual training on the Code, which prohibits human trafficking or any other forms of human rights abuses. QuidelOrtho also launched modern slavery training to applicable Company Employees in April 2026.

8. Assessing Effectiveness

- 8.1 QuidelOrtho plans to keep track of our actions and review our performance in modern slavery compliance by evaluating key performance indicators, such as the number of employees trained, the number of suppliers screened and the number of reported violations, so that we can continue to improve.

9. Approvals

- 9.1 Solely for purposes of compliance with the UK Act, this Report was approved on May 21, 2026 by the Board of Directors of Ortho UK and signed by the undersigned Director of Ortho UK.

DocuSigned by:

7CB8FB32706947E...

Andrew Corkum

Director, Ortho-Clinical Diagnostics